NO20043842L - Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX - Google Patents
Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IXInfo
- Publication number
- NO20043842L NO20043842L NO20043842A NO20043842A NO20043842L NO 20043842 L NO20043842 L NO 20043842L NO 20043842 A NO20043842 A NO 20043842A NO 20043842 A NO20043842 A NO 20043842A NO 20043842 L NO20043842 L NO 20043842L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- processes
- forms
- atorvastatin hemicalcium
- new
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043842L true NO20043842L (no) | 2004-09-14 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043842A NO20043842L (no) | 2002-02-15 | 2004-09-14 | Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (no) |
| JP (2) | JP2005519076A (no) |
| KR (1) | KR100724515B1 (no) |
| CN (1) | CN100406436C (no) |
| AU (1) | AU2003217653A1 (no) |
| CA (1) | CA2475864A1 (no) |
| DE (1) | DE03713610T1 (no) |
| ES (1) | ES2241507T1 (no) |
| HR (1) | HRP20040768A2 (no) |
| IS (1) | IS7402A (no) |
| MX (1) | MXPA04007939A (no) |
| NO (1) | NO20043842L (no) |
| PL (1) | PL372303A1 (no) |
| WO (1) | WO2003070702A1 (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| HRP20040767A2 (en) | 2002-02-19 | 2004-12-31 | Teva Pharma | Desolvating solvates of atorvastatin hemi-calcium |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| WO2006012499A2 (en) * | 2004-07-22 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| SK288276B6 (sk) * | 2005-04-08 | 2015-06-02 | Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság | Spôsob prípravy kryštalickej polymorfnej formy hemivápenatej soli atorvastatínu |
| ATE466840T1 (de) | 2005-11-21 | 2010-05-15 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium |
| TW200745026A (en) | 2005-12-13 | 2007-12-16 | Teva Pharma | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| CN101657419A (zh) * | 2007-03-02 | 2010-02-24 | 东亚制药株式会社 | 吡咯基庚酸衍生物的新晶型 |
| KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| KR101324862B1 (ko) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| PE20160945A1 (es) | 2013-11-15 | 2016-09-26 | Akebia Therapeutics Inc | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas |
| CN105055357A (zh) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| DE69634054T2 (de) * | 1995-07-17 | 2005-12-08 | Warner-Lambert Co. | Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| KR20020063190A (ko) * | 1999-11-17 | 2002-08-01 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 칼슘의 다형태 |
| DE60026737T2 (de) * | 1999-12-17 | 2006-09-21 | Pfizer Science And Technology Ireland Ltd., Dun Laoghaire | Verfahren zur herstellung von kristallin atorvastin kalcium |
| EP1584616A1 (en) * | 1999-12-17 | 2005-10-12 | Pfizer Science and Technology Ireland Limited | Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt |
| JP2004513956A (ja) * | 2000-11-03 | 2004-05-13 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムｖｉｉ型 |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| DE60137364D1 (de) * | 2000-12-27 | 2009-02-26 | Teva Pharma | Kristalline formen von atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| CN1524073A (zh) * | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀） |
| EP2292600A1 (en) * | 2001-07-30 | 2011-03-09 | Dr. Reddy's Laboratories Ltd. | Crystaline forms VI and VII of atorvastatin calcium |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 DE DE03713610T patent/DE03713610T1/de active Pending
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/ja not_active Withdrawn
- 2003-02-19 ES ES03713610T patent/ES2241507T1/es active Pending
- 2003-02-19 CN CNB038082071A patent/CN100406436C/zh not_active Expired - Fee Related
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/hr not_active Application Discontinuation
- 2003-02-19 PL PL03372303A patent/PL372303A1/xx not_active Application Discontinuation
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/es unknown
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/ko not_active Expired - Fee Related
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/is unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/no not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IS7402A (is) | 2004-08-13 |
| EP1480950A1 (en) | 2004-12-01 |
| ES2241507T1 (es) | 2005-11-01 |
| PL372303A1 (en) | 2005-07-11 |
| KR100724515B1 (ko) | 2007-06-04 |
| CA2475864A1 (en) | 2003-08-28 |
| CN1646490A (zh) | 2005-07-27 |
| EP1480950A4 (en) | 2005-05-18 |
| JP2005519076A (ja) | 2005-06-30 |
| WO2003070702A1 (en) | 2003-08-28 |
| AU2003217653A1 (en) | 2003-09-09 |
| MXPA04007939A (es) | 2004-11-26 |
| JP2009235083A (ja) | 2009-10-15 |
| HRP20040768A2 (en) | 2005-06-30 |
| KR20040081202A (ko) | 2004-09-20 |
| DE03713610T1 (de) | 2005-10-20 |
| CN100406436C (zh) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043842L (no) | Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX | |
| NO20032425D0 (no) | Nye krystallformer av atorvastatin-hemi-kalsium og fremgangsmåter for deresfremstilling, samt nye fremgangsmåter for fremstilling av andreformer | |
| NO20035193D0 (no) | Nye pyrrolderivater som farmasöytiske midler | |
| NO20034187D0 (no) | Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer | |
| DK1701946T3 (da) | 1-piperazin- og 1-homopiperazincarboxylatderivater, deres fremstilling og deres terapeutiske anvendelse som inhibitorer af FAAH-enzymet | |
| NO20043726L (no) | Heteroarylforbindelser anvendelige som inhibitorer av GSK-3 | |
| NO20061396L (no) | Nye heterocykliske forbindelser som HSP90-inhibitorer | |
| WO2005032472A3 (en) | Pyrrolidine and piperidine derivatives as factor xa inhibitors | |
| IS7768A (is) | Aðferðir til framleiðslu, einangrunar og hreinsunar epóþílóns B, og röntgengeisla kristallabyggingar epóþílóns B | |
| NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
| ATE412649T1 (de) | Substituierte heteroarylbenzofuransäuren | |
| ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
| NO20054876D0 (no) | Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser | |
| HRP20150163T1 (xx) | Postupak za proizvodnju n-supstituiranih 2-cijanopirolidina | |
| NO20040996L (no) | Nye forbindelser og sammensetninger som catepsin-inhibitorer | |
| NO20035328D0 (no) | Nye forbindelser og preparater som katepsinhibitorer | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
| NO331195B1 (no) | Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter. | |
| DE602004023786D1 (de) | Herstellung von hochreinem Alkylgallium | |
| NO20055657D0 (no) | Nye bioisostaererav aktinonin | |
| NO20044332L (no) | Forbedret fremgangsmate for fremstilling av nevirapine | |
| NO20050885L (no) | Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
| NO20043610L (no) | Fenylpyrimidinaminer som IgE inhibitorer | |
| NO20053910L (no) | Nye piperazinderivater og deres anvendelse som syntesemellomprodukter. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |